Drug Trial Radar · NCT01966471
A Study of Trastuzumab Emtansine (Kadcyla) Plus Pertuzumab (Perjeta) Following Anthracyclines in Comparison With Trastuzumab (Herceptin) Plus Pertuzumab and a Taxane Following Anthracyclines as Adjuvant Therapy in Participants With Operable HER2-Positive Primary Breast Cancer
Last checked: Nov 20, 2026Latest source record: Jun 14, 2022 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
1,846
Actual
Start
Jan 31, 2014
Primary completion
Nov 27, 2019
Study completion Jun 4, 2021
Sponsor
- Lead sponsor
- Hoffmann-La RocheRoche (Genentech) (RHHBY)
- Sponsor type
- Industry
- First posted
- Oct 21, 2013
Design
- Study type
- Interventional
- Phase
- Phase 3
- Allocation
- Randomized
- Model
- Parallel
- Masking
- None
- Primary purpose
- Treatment
- Who can join
- All sexes, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
This two-arm, randomized, open-label, multicenter study will evaluate the efficacy and safety of trastuzumab emtansine in combination with pertuzumab versus trastuzumab in combination with pertuzumab and a taxane as adjuvant therapy in participants with human epidermal growth (HER) factor 2 (HER2)-positive primary invasive breast cancer. Following surgery and anthracycline-based chemotherapy, participants will receive either trastuzumab emtansine at a dose of 3.6 milligrams per kilogram (mg/kg) and pertuzumab at a dose of 420 milligrams (mg) intravenously (IV) every 3 weeks (q3w) or trastuzumab at a dose of 6 mg/kg and pertuzumab at a dose of 420 mg IV q3w in combination with a taxane.
Conditions
- Breast Cancer
Interventions
Trastuzumab EmtansineDrug
Trastuzumab emtansine IV infusion (duration 90 minutes) will be administered at 3.6 mg/kg q3w for up to 18 cycles (1 cycle = 21 days).
TrastuzumabDrug
Trastuzumab IV infusion (duration 90 minutes) will be administered at 8 mg/kg loading dose followed by 6 mg/kg IV q3w for up to 18 cycles (1 cycle = 21 days).
PertuzumabDrug
Pertuzumab infusion (duration 60 minutes) will be administered at 840 mg loading dose followed by 420 mg IV q3w for up to 18 cycles (1 cycle = 21 days).
PaclitaxelDrug
IV infusion of paclitaxel 80 mg/m\^2 once weekly may be administered concurrently with trastuzumab in combination with pertuzumab for 12 weeks.
EpirubicinDrug
3 to 4 cycles (1 cycle = 21 days) of standard of care anthracycline-based chemotherapy using epirubicin may be administered in both Arms 1 and 2 as per discretion of the investigator and local prescribing information/institutional guidelines.
DoxorubicinDrug
3 to 4 cycles (1 cycle = 21 days) of standard of care anthracycline-based chemotherapy using doxorubicin may be administered in both Arms 1 and 2 as per discretion of the investigator and local prescribing information/institutional guidelines.
DocetaxelDrug
IV infusion either docetaxel every 3 weeks (q3w) (at 100 milligram per square meter \[mg/m\^2\] for 3 cycles (1 cycle = 21 days); at 75 mg/m2 for 4 cycles; or start at 75 mg/m\^2 in the first cycle and escalate to 100 mg/m\^2 if no dose limiting toxicity occurs, for a total of 3 cycles at minimum) may be administered concurrently with trastuzumab in combination with pertuzumab.
CyclophosphamideDrug
3 to 4 cycles (1 cycle = 21 days) of standard of care anthracycline-based chemotherapy using cyclophosphamide (FEC) may be administered in both Arms 1 and 2 as per discretion of the investigator and local prescribing information/institutional guidelines.
5-FluorouracilDrug
3 to 4 cycles (1 cycle = 21 days) of standard of care anthracycline-based chemotherapy using 5-fluorouracil, may be administered in both Arms 1 and 2 as per discretion of the investigator and local prescribing information/institutional guidelines.
Primary outcomes
What the sponsor says the trial is designed to measure.
- Invasive Disease-Free Survival (IDFS) in the Node-Positive SubpopulationTime frame: Last participant randomized to data cut-off date of 27 November 2019 (approximately 70 months). The 3 year IDFS event-free rate was assessed based on the data collected for each participant considering the cut-off date mentioned above.
- Invasive Disease-Free Survival (IDFS) in the Overall PopulationTime frame: First participant randomized up to approximately 7.5 years
Locations
295 sites in 36 countries. Site status is shown where the registry gives one.
HonorHealth Research Institute - Bisgrove
Scottsdale, Arizona
Kaiser Permanente - Oakland
Oakland, California
Kaiser Permanente - Roseville; Oncology Pharmacy
Roseville, California
Kaiser Permanente - Sacramento; Oncology Pharmacy
Sacramento, California
UC Davis Cancer Center; Oncology
Sacramento, California
Southern California Kaiser Permanente
San Diego, California
Kaiser Permanente - San Jose
San Jose, California
Kaiser Permanente - San Leandro
San Leandro, California
Kaiser Permanente - South SF; Oncology Clinical trials
South San Francisco, California
Stanford University School of Medicine
Stanford, California
Kaiser Permanente - Vallejo
Vallejo, California
Kaiser Permanente - Walnut Creek; Oncology Pharmacy
Walnut Creek, California
Holy Cross Hospital
Fort Lauderdale, Florida
Florida Cancer Specialists; SCRI
Fort Myers, Florida
Florida Cancer Specialists; Saint Petersburg
St. Petersburg, Florida
University Cancer & Blood Center, LLC; Research
Athens, Georgia
Georgia Cancer Specialists
Atlanta, Georgia
Central Georgia Cancer Care PC
Macon, Georgia
Quincy Medical Group; Canc Ctr at Blessing Hosp
Quincy, Illinois
Carle Cancer Center
Urbana, Illinois
Indiana University
Indianapolis, Indiana
Cancer Center of Kansas
Wichita, Kansas
Anne Arundel Health System Research Instit-Annapolis Oncology Ctr
Annapolis, Maryland
Mercy Medical Center
Baltimore, Maryland
Dana Farber Cancer Inst.
Boston, Massachusetts
Beth Israel Deaconess Med Ctr
Boston, Massachusetts
Karmanos Cancer Institute..
Detroit, Michigan
Henry Ford Hospital; Hematology Oncology
Detroit, Michigan
US oncology research at Minnesota Oncology
Saint Paul, Minnesota
Mercy Medical Research Institute
Springfield, Missouri
Dartmouth Hitchcock Med Center
Lebanon, New Hampshire
Rutgers Cancer Institute of New Jersey
New Brunswick, New Jersey
Memorial Sloan-Kettering Cancer Center
Commack, New York
ProHEALTH Care Associates LLP
Lake Success, New York
Levine Cancer Institute
Charlotte, North Carolina
Duke University Medical Center
Durham, North Carolina
Cone Health Cancer Center
Greensboro, North Carolina
Oncology Hematology Care Inc
Cincinnati, Ohio
Mercy Clinic Oklahoma Communties, Inc
Oklahoma City, Oklahoma
Magee-Woman's Hospital
Pittsburgh, Pennsylvania
Showing 40 of 295 sites, US sites first. The full list is on the registry record.
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.